Rajeev Modi Acquires 4,911 Shares of Elanco Animal Health (NYSE:ELAN) Stock

Elanco Animal Health Incorporated (NYSE:ELAN) insider Rajeev Modi acquired 4,911 shares of the stock in a transaction on Friday, May 15th. The shares were bought at an average price of $20.35 per share, with a total value of $99,938.85. Following the purchase, the insider directly owned 160,812 shares of the company’s stock, valued at $3,272,524.20. The trade was a 3.15% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Elanco Animal Health Stock Up 5.3%

Elanco Animal Health stock opened at $20.84 on Thursday. The stock has a market cap of $10.41 billion, a PE ratio of -41.68, a price-to-earnings-growth ratio of 2.13 and a beta of 1.69. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. Elanco Animal Health Incorporated has a one year low of $12.40 and a one year high of $27.72. The stock has a fifty day moving average of $23.10 and a 200 day moving average of $23.29.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.Elanco Animal Health’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, sell-side analysts predict that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Analysts Set New Price Targets

ELAN has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $24.00 to $30.00 in a report on Thursday, January 22nd. KeyCorp boosted their price target on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Leerink Partners boosted their price target on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday, February 24th. Finally, UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $28.20.

Hedge Funds Weigh In On Elanco Animal Health

Hedge funds have recently made changes to their positions in the business. NewEdge Advisors LLC boosted its stake in shares of Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after acquiring an additional 627 shares during the period. Huntington National Bank boosted its stake in shares of Elanco Animal Health by 136.7% in the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after acquiring an additional 1,087 shares during the period. Root Financial Partners LLC boosted its stake in shares of Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after acquiring an additional 592 shares during the period. Uniplan Investment Counsel Inc. bought a new position in shares of Elanco Animal Health in the fourth quarter worth about $41,000. Finally, Whittier Trust Co. of Nevada Inc. boosted its stake in shares of Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after acquiring an additional 900 shares during the period. Institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.